Conferences - Results from #9460

ASCO GU 2017: A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). - Session Highlights February 18, 2017

ASCO GU 2017: Evolving Treatment Using Tyrosine Kinase Inhibitors and Immunotherapy in Metastatic Renal Cell Carcinoma - Session Highlights February 18, 2017

ASCO GU 2017: Adjuvant Therapy of Renal Cell Carcinoma: Current Controversies - Session Highlights February 18, 2017

ASCO GU 2017: Imaging as Biomarker of Response in Advanced Renal Cell Carcinoma - Session Highlights February 18, 2017

ASCO GU 2017: Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC) - Session Highlights February 18, 2017

ASCO GU 2017: Evolution of circulating tumor DNA profile from 1st line to 2nd line therapy in metastatic renal cell carcinoma. - Session Highlights February 18, 2017

ASCO GU 2017: Cryoablation of cT1 renal masses in the “healthy” patient: Early outcomes from Mayo Clinic. - Session Highlights February 18, 2017

ASCO GU 2017: Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation. - Session Highlights February 18, 2017

ASCO GU 2017: How best to treat locally advanced penile cancer: radiation versus surgery - Session Highlights February 18, 2017

ASCO GU 2017: Orphan Cancers with Opportunities for Improved Treatment: Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy - Session Highlights February 18, 2017

ASCO GU 2017: Phase II Study Supports Potential For Genentech’s TECENTRIQ® (ATEZOLIZUMAB) PLUS AVASTIN® (BEVACIZUMAB) For People With Locally Advanced or Metastatic Renal Cell Carcinoma - Session Highlights February 18, 2017

ASCO GU 2017: Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses. - Session Highlights February 18, 2017

ASCO GU 2017: Use of Ablation in Small Renal Tumors - Session Highlights February 18, 2017

ASCO GU 2017: Novel Imaging Modality: Radiographic Biopsy - Session Highlights February 18, 2017

ASCO GU 2017: Contemporary Role of Percutaneous Biopsy for the Small Renal Mass - Session Highlights February 18, 2017

ASCO GU 2017: The Evolving Role of Active Surveillance in Small Renal Tumors - Session Highlights February 18, 2017

ASCO GU 2017: Genetic Conditions With a Predisposition to Renal Cell Carcinoma - Session Highlights February 18, 2017

ASCO GU 2017: Con: Is There a Role for Treatment Intensification for Patients With Poor Prognosis Germ-Cell Tumors With Unfavorable Marker Decline? - Session Highlights February 18, 2017

ASCO GU 2017: Debate - Pro: Is There a Role for Treatment Intensification for Patients With Poor Prognosis Germ-Cell Tumors With Unfavorable Marker Decline? - Session Highlights February 18, 2017

ASCO GU 2017: Actionable targets in germ cell tumors - Session Highlights February 18, 2017

Page 474 of 577